Patients’ own bone-marrow stromal (stem) cells could be used to treat resistant tuberculosis (TB), according to a preliminary study by an international research team.
Conventional treatment for multi-drug resistant TB uses a combination of antibiotics which are toxic to patients. In this study, published today in The Lancet Respiratory Medicine, researchers claim using patients’ own bone-marrow stromal cells is safe and could help overcome the body’s excessive inflammatory response, repair and regenerate inflammation-induced damage to lung tissue, and lead to improved cure rates.
The World Health Organization estimates that in Eastern Europe, Asia, and South Africa 450,000 people have multi-drug resistant TB, and around half of these will fail to respond to existing treatments.
TB bacteria trigger an inflammatory response in immune cells and surrounding lung tissue that can cause immune dysfunction and tissue damage. Bone-marrow mesenchymal stromal cells (MSCs) are known to migrate to areas of lung injury and inflammation and repair damaged tissue. They also modify the body’s immune response and could boost the clearance of TB bacteria.
In this phase 1 safety study, 30 patients with multi-drug resistant or extensively-drug resistant TB aged 21–65 years old receiving standard TB antibiotic treatment were also given an infusion of around 10 million of their own stromal cells. The cells were obtained from the patient’s own bone marrow, then cultured into large numbers in the laboratory before being re-transfused into the same patient.
MSC infusion was generally safe and well tolerated. During the 6 months follow-up, no serious adverse events were recorded. The most common grade 1 or 2 adverse events were high cholesterol levels (14 of 30 patients), nausea (11 patients), and lymphopenia or diarrhoea (10 patients).
Further analyses showed 16 patients treated with MSCs were deemed cured at 18 months compared with only 5 of 30 TB patients with similar disease not treated with MSCs.
Co-author Professor Alimuddin Zumla, Professor of Infectious Diseases and International Health at UCL and a BRC-supported researcher, said: “The results of this novel and exciting study show that the current challenges and difficulties of treating multi-drug resistant TB are not insurmountable, and they bring a unique opportunity with a fresh solution to treat hundreds of thousands of people who die unnecessarily of drug-resistant TB.
The Latest on: Multi-drug resistant TB
[google_news title=”” keyword=”Multi-drug resistant TB” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Multi-drug resistant TB
- Sudan: UNDP delivers essential medicines for HIV, TB treatmenton July 30, 2024 at 3:06 am
More than 20 metric tons of essential medicines, diagnostics, and supplies have arrived, delivered by UNDP Sudan, to ensure the continuation of HIV and TB treatment for patients throughout the country ...
- Tuberculosis Newson July 28, 2024 at 5:00 pm
May 8, 2024 — Researcher found that exposed individuals with confirmed TB infection -- i.e. a positive skin or blood test -- should receive priority treatment in settings with a low prevalence ...
- Woman who went on the lam with untreated TB is now curedon July 24, 2024 at 8:01 am
"She's cured!" Health officials in Washington state are celebrating the clean bill of health for one particularly notable resident: the woman who refused to isolate and get treatment for her active ...
- Cases of World’s Deadliest Bacterial Illness Rising in New Yorkon July 23, 2024 at 3:10 am
After a 30-year decline, cases of a life-threatening bacterial infection are rebounding across New York State.
- News tagged with tuberculosison July 18, 2024 at 5:00 pm
Antibiotic resistance is a growing problem in (extensively) multi-drug-resistant tuberculosis. Prevention relies on screening programs and vaccination, usually with Bacillus Calmette-Guérin (BCG ...
- J&J’s multidrug-resistant TB treatment Sirturo granted full EC and FDA approvalson July 7, 2024 at 5:00 pm
The EC has granted the drug full approval to treat pulmonary multidrug-resistant tuberculosis (MDR-TB) as part of an appropriate combination regimen in adult and paediatric patients aged five years ...
- Sirturo approved for multi-drug resistant TBon July 7, 2024 at 5:00 pm
The spread of multi-drug resistant TB is a growing global health problem, not just in the least developed nations, but also in developed countries, where the disease is staging a comeback.
- J&J's SIRTURO Receives Full Approval From FDA, EC For Multi-Drug-Resistant Tuberculosison July 3, 2024 at 6:18 am
The study evaluated the efficacy and safety of an all-oral bedaquiline-containig regimen for multidrug-resistant tuberculosis (MDR-TB). Compared to a 9-month injectable-based regimen, the ...
- Bedaquiline won’t remain ‘wonder drug’ for TB, say expertson July 1, 2024 at 5:00 pm
New Delhi: The government on Monday launched bedaquiline, billed as a wonder drug to treat multi-drug-resistant (MDR) tuberculosis, in collaboration with Johnson & Johnson. Johnson & Johnson has ...
- New biomarker identified for predicting adverse events of tuberculosis therapyon July 1, 2024 at 5:00 pm
Every year, an estimated 410,000 people worldwide contract a multidrug-resistant form of tuberculosis. During treatment, approximately a quarter of patients experience linezolid-associated adverse ...
via Bing News
